Based in Cambridge MA, Vigeo Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel therapeutics to effectively treat multiple types of cancer and improve the lives of patients. Vigeo is the first, and only, company developing therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction.
